ReviewTherapeutic advances in gastroenterology2017
MMX
Review in Therapeutic advances in gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 37 citations in OpenAlex.
- A randomized open label pilot study evaluating the efficacy of two dosing regimens of rifamycin SV MMX in the treatment of small intestinal bacterial overgrowth.BMC gastroenterology · 2025Trial
- Enteric-Coated Capsules Providing Reliable Site-Specific Drug Delivery to the Distal Ileum.Molecular pharmaceutics · 2024Article
- Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches.Pharmacology & therapeutics · 2024Review
- A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system.Frontiers in pharmacology · 2024Article
- Self-Assembled Polymers for Gastrointestinal Tract Targeted Delivery through the Oral Route: An Update.Polymers · 2023Review
- Efficacy and safety of medical therapies in microscopic colitis: a systematic review and network meta-analysis.Therapeutic advances in gastroenterology · 2023Article
- Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α.The Korean journal of internal medicine · 2022Review
- A Case of Stevens-Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis.Medicina (Kaunas, Lithuania) · 2022Article
- pH-dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review).Biomedical reports · 2021Review
- Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety.Therapeutics and clinical risk management · 2021Review
- Complicated diverticulitis mimicking colonic carcinoma: combined approach with endoscopy and budesonide.BMJ case reports · 2019Article
- Rifamycin SV MMXClinical drug investigation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Multimatrix
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.